Expression of p21 in non small cell lung cancer relationship with PCNA

被引:0
|
作者
Groeger, AM
Caputi, M
Esposito, V
Baldi, A
Rossiello, R
Santini, D
Mancini, A
Kaiser, HE
Baldi, F
机构
[1] Univ Vienna, Dept Cardiothorac Surg, Vienna, Austria
[2] Univ Naples 2, Dept Resp Dis, Naples, Italy
[3] Regina Elena Inst Canc Res, Lab Cell Metab & Pharmacokinet, Ctr Expt Res, I-00161 Rome, Italy
[4] Univ Naples 2, Serv Pathol Anat L Armanni, Naples, Italy
[5] Libero Inst Univ, Rome, Italy
[6] Univ Maryland, Dept Pathol, Baltimore, MD 21201 USA
[7] Univ Vienna, Dept Expt Pathol, A-1010 Vienna, Austria
关键词
p21; immunohistochemistry; pcna; non small cell lung cancer;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The first cyclin dependent kinase inhibitor to be discovered was the p21 cdk interacting protein (a.k.a., WAF1, Cip1, CAP20, Sdi1, mda6). p21 expression may or. may not be dependent on p53. This pathway also inhibits DNA replication by merit of p21's interaction with PCNA, but it has also been shown that this same inhibitory interaction with p21 does nor affect PCNA DNA repair abilities. We assessed the immunohistochemical expression of p21 protein in 60 curative surgical resected non small cell lung cancers I elating it to the expression of PCNA to clarify the contribution of the p21/PCNA pathway to the development of NSCLC. We did not find any relationship between PCNA and p21 expression. This last result may indicate that the mechanism by which PCNA controls the DNA repair is the most important activity of this protein during lung cancer progression and development, compared to its contribution to cell proliferation. In fact, this last event is strongly counteracted by p21 expression, which in this last case works as an inhibitor of PCNA expression. In conclusion this study highlighted the important role of the p21/PCNA pathway in lung carcinogenesis, pointing out the contribution of PCNA to the response to lung aggression and nor only it's role as a proliferation index. Therefore, these results offer a background to further study to evaluate potential novel therapeutic approaches to lung cancel treatment.
引用
收藏
页码:3301 / 3305
页数:5
相关论文
共 50 条
  • [31] p21waf1/cip1mda-6 expression in non-small-cell lung cancer:: Relationship to survival
    Caputi, M
    Esposito, V
    Baldi, A
    De Luca, A
    Dean, C
    Signoriello, G
    Baldi, F
    Giordano, A
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1998, 18 (02) : 213 - 217
  • [32] Long noncoding RNA AFAP1-AS1 predicts a poor prognosis and regulates non–small cell lung cancer cell proliferation by epigenetically repressing p21 expression
    Dandan Yin
    Xiyi Lu
    Jun Su
    Xuezhi He
    Wei De
    Jinsong Yang
    Wei Li
    Liang Han
    Erbao Zhang
    Molecular Cancer, 17
  • [33] Clinicopathological Significance of E-cadherin and PCNA Expression in Hunman Non-small Cell Lung Cancer
    Zhu, Yi-fei
    Zheng, Shi-Ying
    Jiang, Dong
    Zhao, Jun
    2010 4TH INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND BIOMEDICAL ENGINEERING (ICBBE 2010), 2010,
  • [34] Clinicopathological significance of E-cadherin and PCNA expression in human Non-small Cell Lung Cancer
    Zheng, Shi Ying
    Li, Hong
    Jiang, Dong
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S893 - S893
  • [35] Clinicopathological Significance of E-cadherin and PCNA Expression in Hunman Non-small Cell Lung Cancer
    Jianwei Ma1 Kai Fan2 Yanli Zhang2 Dawei Song2 Jianmei Ma2 1 Department of thoracic surgery
    Chinese Journal of Clinical Oncology, 2008, (02) : 87 - 92
  • [36] Expression of FATS in non-small cell lung cancer and its relationship with prognosis
    张铁梅
    China Medical Abstracts(Internal Medicine), 2020, 37 (01) : 41 - 42
  • [37] Endocan expression and relationship with survival in human non-small cell lung cancer
    Grigoriu, Bogdan Dragos
    Depontieu, Florence
    Scherpereel, Arnaud
    Gourcerol, Delphine
    Devos, Patrick
    Ouatas, Taoufik
    Lafitte, Jean-Jacques
    Copin, Marie-Christine
    Tonnel, Andre-Bernard
    Lassalle, Philippe
    CLINICAL CANCER RESEARCH, 2006, 12 (15) : 4575 - 4582
  • [38] P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment
    Zhao, Yi-Fan
    Wang, Chong-Ren
    Wu, Yan-Ming
    Ma, Sheng-Lin
    Ji, Yuan
    Lu, Yan-Jun
    BIOMEDICINE & PHARMACOTHERAPY, 2011, 65 (03) : 151 - 156
  • [39] Pro-survival roles for p21(Cip1/Waf1) in non-small cell lung cancer
    Cutty, S. J.
    Hughes, F. A.
    Ortega-Prieto, P.
    Desai, S.
    Thomas, P.
    Fets, L., V
    Secrier, M.
    Barr, A. R.
    BRITISH JOURNAL OF CANCER, 2025, 132 (05) : 421 - 437
  • [40] Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer
    Wang, Honggang
    Fei, Zhenghua
    Jiang, Hao
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2017, 134 (03) : 190 - 196